stockrow
Saturday 7 November 2026
Export ENTA’s income statement to Excel — free account
Enanta Pharmaceuticals, Inc.
ENTA Healthcare Biotechnology
Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024.
- Revenue
- −21.6%
- EPS
- +21.2%
- Free cash flow
- −157.5%
Quarter to June 2026, against a year earlier
11.00
0.92
+9.13%
Follow ENTA
Alert me
Enanta Pharmaceuticals, Inc. (ENTA) P/E ratio
Enanta Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 382× (July 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 25.2× | 11.65% |
| FY2018 | 22.6× | (55.80%) |
| FY2017 | 51.2× | 121.06% |
| FY2016 | 23.1× | 170.83% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 382×
Ten-year median
0.0×
Current reading's percentile
58
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| BNTC Benitec Biopharma Limited compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| AGEN Agenus Inc. compare | 10.7× |
| SCTX Scribe Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)